Navigation Links
Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis

e able to anticipate providing a product addressing such an unmet therapeutic need in a paediatric population" says Florence Binlich Novagali's Medical Director who adds "we are also impressed by the high level of motivation and enthusiasm of the experts who participated in the trial".

"As practicing clinicians, we are very pleased to observe that Vekacia(R) brought significant benefits even in severe forms of the disease" declared Pr Ben Ezra, study lead investigator "It can confidently be said that now, the treating ophthalmologists may have, finally, a new and efficient tool for the management of VKC".

Based upon the results of the study, Novagali plans to file European Marketing Authorization mid-2007.

About Novagali Pharma: http://www.novagali.com

Novagali Pharma SA is an emerging ophthalmic pharmaceutical company based in the Genopole biocluster in Evry, France, that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 6 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis; Cationorm(R), a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, the firm has raised a total amount of Euro 44 million in 3 series of financing.

CONTACT: Press Contact: Genevieve Garrigos, +33(0)6-82-85-58-99, genevieve.garrigos@novagali.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) ... previously announced acquisition of SloMedical S.R.O., a ... ranging from tubing sets to complex devices ... Flextronics provides a broad set of capabilities ... customers. Terms of the deal were not ...
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... Dec. 15 Certified healthcare providers who ... complications from the H1N1 flu virus may now ... the Department of Health announced today. ,, ... everyone because approximately 3.2 million doses of vaccine ... it to individuals in the priority groups. ,, ...
Breaking Medicine Technology:Flextronics Completes SloMedical Acquisition 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Upending textbook science on Alzheimers disease 61940 1Upending textbook science on Alzheimers disease 61940 2Killer fungus threatening amphibians 10867 1NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 1NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 3
... Use of Fujirebio Diagnostics, , HE4 Test with CA125 ... Pa., Jan. 26 A pivotal clinical trial published ... Gynecologic Oncology demonstrated the utility of combining Fujirebio ... in estimating the risk of epithelial ovarian cancer in ...
... Identified, Versus MenNEW YORK, Jan. 26 Hypertrophic Cardiomyopathy ... thickening of the heart wall muscle and is the ... young adults (<40). More importantly, although heart disease ... Cardiomyopathy Association ( www.4HCM.org ) warns women remain untreated ...
Other Medicine Technology:Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 2Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 3Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 4Cardiac Disease in Women Remains Untreated for Decades 2
(Date:12/15/2009)... 15 SUMMARY: The U.S. ... Protection and Affordable Care Act that would have ... for the safe and legal importation of lower ... by AARP and sponsored by Senators Dorgan, Snowe, ... and helped to bring down the skyrocketing costs ...
(Date:12/15/2009)... (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization ... all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders ... Description of Votes ... Votes Non-, Matter ... For Against ...
(Date:12/15/2009)... Calif., Dec. 15 Palo Alto Networks(TM), ... University has deployed its PA-4000 Series next-generation firewalls ... and for enhanced visibility and control over applications ... is a Japanese national university with eight facilities ... 1949 by integrating a number of academic schools ...
(Date:12/15/2009)... be donated to the Lupus Foundation of America and ... Dec. 15 Julian Lennon, son of the ... their new digital single, "LUCY," to raise funds for ... 15, 2010, 100 percent of the proceeds from downloading ... Foundation of America (LFA), and the Saint Thomas, Lupus ...
(Date:12/15/2009)... YORK, Dec. 15 Vitech Systems Group, ... Relationship Management (CRM) software, announced today that it ... implementation for the Screen Actors Guild-Producers Pension & ... advanced customer service capabilities to SAG-PH call center ... system was installed using Vitech,s V3 Benefits Administration ...
Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2
... disease care, study finds , , TUESDAY, Oct. 2 (HealthDay ... rates of chronic disease in the United States, with ... a new study finds. , It,s an expensive problem, ... and heart disease account for some $100 to $150 ...
... MIT Holding, Inc. (OTCBB: MITD - News), has signed ... to stop the spread of infectious diseases. Dr. ... and Director of the Biodefense and Infectious Disease Laboratory ... College of Public Health, Georgia Southern University, will oversee ...
... PA, October 2, 2007 The first significant genetic ... reported. PMDD is a very severe form of ... PMDD is heritable, affects 5-8% of women, and is ... irritability, marked depressed mood, anger, headaches, weight gain and ...
... /PRNewswire/-- Meretek Diagnostics, Inc. and,Otsuka America Pharmaceutical, Inc. ... the two companies. The merger forms a new ... America Pharmaceutical,Inc. OAPI was established in 1989 ... by Otsuka Pharmaceutical Co., Ltd. (OPC). Meretek Diagnostics,was ...
... Fibertec, a division of,Filtrona plc, developer of fiber-based ... celebrated the completion,of the recent expansion of its ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061127/DCM011LOGO ) The ... the size of,production floor space and an expanded ...
... TOWN, W.V., Oct. 2 /PRNewswire-FirstCall/-- ReBuilder Medical,Technologies, Inc. ... the,increasing demand for its products it has had ... in the past three weeks alone. (Logo: ... PhD, CEO of ReBuilder, stated, "We have been,marketing ...
Other Medicine News:Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger 2Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 3
... ACTH (adrenocorticotropic hormone) is synthesized in ... gland and is secreted into the peripheral ... approximately 20 minutes [1]. ACTH is secreted ... the hypothalamus [1]. The actions of CRF ...
... chorionic gonadotropin (hCG) is a two chain ... the chorionic tissue of the placenta and ... during pregnancy. Produced by the trophoblastic epithelium ... the corpus luteum in the early stages ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
... Medicals AUDICOR is the first, easy-to-use, ... worldwide quickly rule-in cardiac dysfunction including ... and other high-risk cardiac conditions. Designed ... workflow, AUDICOR products enable clinicians caring ...
Medicine Products: